The stock of Rhythm Pharmaceuticals Inc (RYTM) has gone up by 29.14% for the week, with a 24.08% rise in the past month and a 53.77% rise in the past quarter. The volatility ratio for the week is 3.66%, and the volatility levels for the past 30 days are 3.51% for RYTM.. The simple moving average for the past 20 days is 30.46% for RYTM’s stock, with a 47.09% simple moving average for the past 200 days.
Is It Worth Investing in Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) Right Now?
Company’s 36-month beta value is 2.37.Analysts have differing opinions on the stock, with 8 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RYTM is 58.19M, and currently, short sellers hold a 8.18% ratio of that floaft. The average trading volume of RYTM on July 09, 2025 was 667.39K shares.
RYTM) stock’s latest price update
Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) has experienced a rise in its stock price by 29.74% compared to its previous closing price of $65.14. However, the company has seen a gain of 29.14% in its stock price over the last five trading days. globenewswire.com reported 2025-07-09 that — Bivamelagon achieved BMI reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts, respectively, at 14 weeks — — Post-hoc analysis showed BMI reductions in bivamelagon trial were consistent with BMI reductions achieved by setmelanotide in past trials in similar patient populations —
Analysts’ Opinion of RYTM
Many brokerage firms have already submitted their reports for RYTM stocks, with Leerink Partners repeating the rating for RYTM by listing it as a “Outperform.” The predicted price for RYTM in the upcoming period, according to Leerink Partners is $88 based on the research report published on July 07, 2025 of the current year 2025.
BofA Securities, on the other hand, stated in their research note that they expect to see RYTM reach a price target of $63. The rating they have provided for RYTM stocks is “Buy” according to the report published on April 07th, 2025.
Stifel gave a rating of “Buy” to RYTM, setting the target price at $78 in the report published on March 05th of the current year.
RYTM Trading at 33.30% from the 50-Day Moving Average
After a stumble in the market that brought RYTM to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 20.92% of gains for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RYTM starting from Garfield Alastair, who sale 1,319 shares at the price of $64.81 back on Jul 02 ’25. After this action, Garfield Alastair now owns 3,126 shares of Rhythm Pharmaceuticals Inc, valued at $85,483 using the latest closing price.
German Christopher Paul, the Corporate Controller & CAO of Rhythm Pharmaceuticals Inc, sale 2,069 shares at $67.19 during a trade that took place back on Jun 10 ’25, which means that German Christopher Paul is holding 1,889 shares at $139,016 based on the most recent closing price.
Stock Fundamentals for RYTM
Current profitability levels for the company are sitting at:
- -1.26 for the present operating margin
- 0.89 for the gross margin
The net margin for Rhythm Pharmaceuticals Inc stands at -1.24. The total capital return value is set at -0.63. Equity return is now at value -418.97, with -52.28 for asset returns.
Based on Rhythm Pharmaceuticals Inc (RYTM), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -27.93. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -8.34.
Currently, EBITDA for the company is -238.09 million with net debt to EBITDA at 0.68. When we switch over and look at the enterprise to sales, we see a ratio of 39.87. The receivables turnover for the company is 7.68for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.30.
Conclusion
In a nutshell, Rhythm Pharmaceuticals Inc (RYTM) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
